Epithelial Ovarian Cancer

Although survival analyses did not demonstrate statistically significant independent prognostic associations, the findings support the biological relevance of CDK1 and TOP2A in EOC progression. Collectively, this study provides an integrated computational perspective on CDK1/TOP2A-associated oncogenic signaling and prioritizes Naringin as a preliminary candidate for future experimental investigation in epithelial ovarian cancer.

This review integrates current evidence on the molecular architecture and regulatory functions of BNC2, critically discusses its context-dependent roles across development and disease, and highlights unresolved questions regarding isoform-specific activity, cell-type-specific regulation, downstream target networks, and clinical translation. A clearer understanding of these mechanisms may support the future evaluation of BNC2 as a biomarker, genetic susceptibility locus, molecular stratification factor, and potential therapeutic regulatory node.

These findings provide preliminary evidence that IGF2 gene polymorphisms may be associated with the risk and clinicopathological characteristics of serous EOC in Chinese women.

The HRd rate in this Taiwanese cohort aligns with existing literature. PARPi significantly improved survival in HRd patients, but adverse events necessitate careful hematological monitoring for treatment sustainability.

P=N/A, N=300, Not yet recruiting, Asan Medical Center

These recommendations aim to promote integrated, equitable, standardized FRα testing across Canada and support timely identification of patients eligible for FRα-directed therapy, clinical trial enrollment, and future biomarker-driven treatment strategies.

Regardless of the limited independent prognostic value of individual CSC markers, their combined expression enhanced risk stratification for recurrence and survival in advanced EOC. Multimarker CSC profiling may enhance prognostication and aid in guiding personalized surveillance and therapeutic strategies.

Moreover, the reduction of SLC45A4 expression in CAFs through gene knockdown technology markedly inhibited tumor growth in mice, offering a novel strategy for TME-based EOC treatment. This study not only provides new insights into the mechanisms of CAFs action in EOC progression but also identifies a potential molecular target for the development of TME-based therapeutic strategies for EOC.

By integrating structural, cellular, and energetic readouts using in-silico techniques, we establish a quantitative framework for septin-targeted modulation, generating UR214-9 as a new chemotype that disrupts septin oligomeric assembly via preventing incorporation of SEPT2/7/9, into canonical hetero-octamers, causes defects in cytokinesis, altered cell migration, viability, and remodels septin-actin architectures, ultimately impairing tumor cell growth. Thus, pharmacological targeting of septin assembly represents a tractable strategy to perturb septin-dependent cellular processes in cancer and neurodegenerative diseases with reported septin dysregulation.

We found that the OEC patients with normal CA125 levels tend to have a better prognosis than those with elevated CA125 levels. Multivariate Cox regression analysis showed that age, summary stage, histology, and lymphadenectomy status were important factors affecting the prognosis of EOC patients with normal CA125 level.

Furthermore, while ARMS-PCR panels displayed limited clinicopathological correlations, MethyLight showed significant correlations (P < 0.05). Overall, this pilot study highlights the promise of liquid biopsy-based diagnostics using independent hypermethylated and hypomethylated CpG biomarkers for ovarian cancer detection.

The results of the H-L test showed good fitness. The nomogram model developed in this study exhibits good predictive performance and applicability, and can be used to screen for the risk of recurrence in this population.